U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-07-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-10-0570PMID 20601446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• Endpoints for assessing drug activity in clinical trials.

  2008cited by this paper
• Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.

  2008cited by this paper
• The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

  2007cited by this paper
• Clinical staging and prognostic markers in chronic lymphocytic leukemia.

  2004cited by this paper
• Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma

  2002cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper

• It takes Two: Advancing cancer treatment with two-step nanoparticle delivery.

  2025cites this paper
• Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.

  2025cites this paper
• Incorporating mRNA therapeutics into biological treatments of hematologic malignancies

  2025cites this paper
• Progress in Aptamer Research and Future Applications.

  2025cites this paper
• Identifying highly effective fludarabine-based novel target cancer therapy agents by in silico studies

  2024cites this paper
• Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis

  2023cites this paper
• “A.B.C.” of Immunotherapy in Hematological Malignancies…Promise and Perils

  2022cites this paper
• Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins.

  2022cites this paper
• Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias

  2022influential citation
• When Can We Trust Real‐World Data To Evaluate New Medical Treatments?

  2021cites this paper
• When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?

  2021cites this paper
• Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy

  2021cites this paper
• The promise and perils of immunotherapy.

  2021cites this paper
• B cell modulation strategies in the improvement of transplantation outcomes.

  2020cites this paper
• The applications of anti-CD20 antibodies to treat various B cells disorders.

  2019cites this paper
• Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.

  2019cites this paper
• Resistance to Monoclonal Antibody Therapeutics in Lymphoma

  2019cites this paper
• ANTICANCER MONOCLONAL ANTIBODIES AND THEIR RADIOIMMUNOCONJUGATES - GATEWAY TO THE MORE SUCCESSFUL THERAPY

  2019cites this paper
• Current Knowledge and Perspectives

  2019cites this paper
• Novel insights into the role of aptamers in the fight against cancer

  2019cites this paper
• Engineering Monoclonal Antibodies: Production and Applications

  2018cites this paper
• Monoclonal Antibodies Targeting Hematological Malignancies

  2018cites this paper
• Chronic Lymphocytic Leukemia: A Review of Front‐line Treatment Options, With a Focus on Elderly CLL Patients

  2018cites this paper
• Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

  2018cites this paper
• Pharmacologic Modulation of Human Immunity in the Era of Immuno‐oncology: Something Old, Something New

  2018cites this paper
• The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

  2018cites this paper
• Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.

  2018cites this paper
• Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients

  2017cites this paper
• Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies.

  2017cites this paper
• Monoclonal Antibodies Hypersensitivity: Prevalence and Management.

  2017cites this paper
• Management of adverse reactions to biologic agents.

  2017cites this paper
• Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

  2017cites this paper
• Novel therapy for childhood acute lymphoblastic leukemia

  2017influential citation
• Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia.

  2017cites this paper
• The use of ofatumumab in the treatment of B-cell malignancies.

  2017cites this paper
• Use of Obinutuzumab for B-cell Malignancies

  2017cites this paper
• Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis

  2017cites this paper
• Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*

  2016cites this paper
• The safety profile of monoclonal antibodies for chronic lymphocytic leukemia

  2016cites this paper
• The PI3K/AKT Pathway as a Target for Cancer Treatment.

  2016influential citation
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

  2016cites this paper
• Title : From monoclonal antibodies to small molecules : the development of inhibitors targeting the PD-1 / PD-L 1 pathway

  2016cites this paper
• Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma

  2016cites this paper
• From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.

  2016cites this paper
• Emerging Treatment Options for Adolescents and Young Adults with Relapsed or Refractory Lymphoma

  2016cites this paper
• Hypersensitivity to biological agents-updated diagnosis, management, and treatment.

  2015cites this paper
• Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

  2015cites this paper
• Rapid Desensitization in Immediate Hypersensitivity Reaction to Drugs

  2015cites this paper
• Ofatumumab for treating chronic lymphocytic leukemia: a safety profile

  2015cites this paper
• Ofatumumab in the treatment of non-Hodgkin’s lymphomas

  2015cites this paper
• Ibrutinib in B lymphoid malignancies

  2015cites this paper
• Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma

  2015cites this paper
• Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

  2015cites this paper
• Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.

  2014cites this paper
• Monoclonal antibodies as therapeutics in human malignancies.

  2014cites this paper
• New treatment options for chronic lymphocytic leukemia

  2014cites this paper
• Licensed monoclonal antibodies and associated challenges

  2014cites this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cites this paper
• High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation

  2014cites this paper
• Toxicity of targeted therapeutic agents in lymphoma and management: part 1: monoclonal antibodies and radioimmunotherapy

  2014cites this paper
• Obinutuzumab for the treatment of chronic lymphocytic leukemia.

  2014cites this paper
• Overcoming Immunodeficiency in Chronic Lymphocytic Leukaemia: Current Knowledge and Perspectives

  2014cites this paper
• Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.

  2014cites this paper
• Ibrutinib and indolent B-cell lymphomas.

  2014cites this paper
• Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

  2013cites this paper
• Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

  2013cites this paper
• Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

  2013cites this paper
• Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.

  2013cites this paper
• [Advances in the research of anti-CD20 therapeutic monoclonal antibodies].

  2013influential citation
• False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay.

  2013cites this paper
• Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

  2013cites this paper
• Adverse events to monoclonal antibodies used for cancer therapy

  2013cites this paper
• The molecular determinants of tumor cell sensitivity and resistance to antibody-dependent cellular cytotoxicity (ADCC)

  2013cites this paper
• Characterisation of high and low avidity peptide specific CD8+ T cells using immunologic, transcriptomic and proteomic tools

  2013cites this paper
• Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells

  2013cites this paper
• Relapsed childhood acute lymphoblastic leukaemia.

  2013cites this paper
• Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells

  2013cites this paper
• Unexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in Humans

  2013cites this paper
• Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.

  2013cites this paper
• Przeciwciała monoklonalne w leczeniu przewlekłej białaczki limfocytowej

  2012cites this paper
• Antikörpertherapie bei malignem Lymphom

  2012cites this paper
• Ofatumumab demonstrates activity against rituximab‐sensitive and ‐resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B‐cell lymphoma

  2012cites this paper
• Infections in Leukemia

  2012cites this paper
• Chronic lymphocytic leukemia.

  2012cites this paper
• Chronic lymphocytic leukemia therapy: beyond chemoimmunotherapy.

  2012cites this paper
• Therapeutic antibodies against cancer.

  2012cites this paper
• Editorial : novel and emerging drugs for leukemias.

  2012cites this paper
• Monoclonal antibodies for the treatment of chronic lymphocytic leukemia

  2012cites this paper
• Bendamustine for treatment of chronic lymphocytic leukemia

  2012cites this paper
• Ofatumumab for a rituximab‐allergic child with chronic‐relapsing paraneoplastic opsoclonus–myoclonus

  2012cites this paper
• New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia.

  2011cites this paper
• U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.

  2011cites this paper
• rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

  2011cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Chinese Anti鄄 Cancer a Ssociation

  2011cites this paper
• Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis

  2011cites this paper
• Have we overestimated the benefit of human(ized) antibodies?

  2010cites this paper
• Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cites this paper
• Inhibition of potassium currents as a pharmacologic target for investigation in chronic lymphocytic leukemia.

  2010cites this paper
• Indywidualne strategie terapeutyczne w przewlekłej białaczce limfocytowej Individual therapeutic approaches in chronic lymphocytic leukemia

  2010cites this paper